Zusammenfassung
Das plasmazytoide Urothelkarzinom (PUC) zählt neben dem mikropapillären (MPC), kleinzelligen und dem Tumor vom „nested-type“ zu den seltenen Varianten von Urothelkarzinomen. Die molekulare Charakterisierung von PUC und MPC stellt dabei gegenwärtig unser Forschungsschwerpunkt im Bereich Harnblasenkarzinom dar, welchen wir in Kooperation mit dem Pathologischen Institut Erlangen verfolgen. PUC betreffen ca. 0,9% aller Urothelkarzinome. Die Diagnose solcher seltenen Varianten erlangt immer mehr an Bedeutung, da sich daraus prognostische und möglicherweise auch therapeutische Konsequenzen für den Patienten ergeben. In einer Analyse von 32 PUC konnten wir die bisher umfassendsten Ergebnisse zu grundlegenden molekularen und klinischen Charakteristika dieser Variante präsentieren. MPC wurden bereits in multiplen Organen beschrieben. Mikropapilläre Karzinome der Mamma stellen dabei eine eigene Entität mit charakteristischen genomischen Aberrationen und entsprechenden klinischen und pathologischen Eigenschaften dar.
Abstract
Plasmacytoid urothelial carcinomas (PUC) along with micropapillary urothelial carcinoma (MPC), small cell cancer, and nested-typed tumors are among the rare variations of urothelial carcinomas. The molecular characterization of PUC and MPC is currently the focus of our research on bladder cancer which we are conducting in cooperation with the Institute of Pathology in Erlangen. PUCs account for approximately 0.9% of all urothelial carcinomas. The diagnosis of these rare variants has acquired increasing importance since this may have prognostic and possibly therapeutic consequences for the patients. By analysis of 32 PUCs we were able to demonstrate the most comprehensive results available to date on the underlying molecular and clinical characteristics of these variants. Micropapillary cancers have already been described in multiple organs. Micropapillary breast cancer represent an individual entity with characteristic genomic aberrations and corresponding clinical and pathological features
This is a preview of subscription content, log in via an institution to check access.
Literatur
Robert Koch-Institut (2010) Krebs in Deutschland 2005/2006. Häufigkeiten und Trends, 7. Aufl. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (Hrsg) Berlin
Eble J, Sauter G, Epstein JI, Sesterhenn IA (Hrsg) (2004) Classification of tumours. Pathology and genetics of the tumours of the urinary system and male genital organs. World Health Organization, Lyon
Gaafar A, Garmendia M, de Miguel E et al (2008) Carcinoma urothelial plasmocitoide de vejiga urinaria. Estudio de 7 casos. Actas Urol Esp 32(8):806–810
Mai KT, Park PC, Yazdi HM et al (2006) Plasmacytoid transitional cell carcinoma. Report of seven new cases. Eur Urol 50:1111–1114
Fritsche HM, Burger M, Denzinger S et al (2008) Plasmacytoid urothelial carcinoma of the bladder: histological and clinical features of 5 cases. J Urol 180:1923–1927
Black PC, Brown GA, Dinney CPN (2009) The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol 27(1):3–7
Kamat AM, Gee JR, Dinney CP et al (2006) The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 175(3 Pt 1):881–885
Keck B, Stoehr R, Wach S et al (2010) The plasmacytoid carcinoma of the bladder – rare variant of aggressive urothelial carcinoma. Int J Cancer (Epub ahead of print)
Kamat AM, Dinney CP, Gee JR et al (2007) Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 110(1):62–67
Lopez-Beltran A, Montironi R, Blanca A, Cheng L (2010) Invasive micropapillary urothelial carcinoma of the bladder. Hum Pathol 41(8):1159–1164
Amin MB, Ro JY, el-Sharkawy T et al (1994) Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol 18(12):1224–1232
Amin MB, Tamboli P, Merchant SH et al (2002) Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance. Am J Surg Pathol 26(3):358–364
Siriaunkgul S, Tavassoli FA (1993) Invasive micropapillary carcinoma of the breast. Mod Pathol 6(6):660–662
Smith Sehdev AE, Sehdev PS, Kurman RJ (2003) Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases. Am J Surg Pathol 27(6):725–736
Marchiò C, Iravani M, Natrajan R et al (2008) Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol 215(4):398–410
Weigelt B, Reis-Filho JS (2009) Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 6(12):718–730
Baldwin L, Lee AH, Al-Talib RK, Theaker JM (2005) Transitional cell carcinoma of the bladder mimicking lobular carcinoma of the breast: a discohesive variant of urothelial carcinoma. Histopathology 46(1):50–56
Nigwekar P, Tamboli P, Amin MB et al (2009) Plasmacytoid urothelial carcinoma detailed analysis of morphology with clinopathologic correlation in 17 cases. Am J Surg Pathol 33(3):417–424
Lotan TL, Ye H, Melamed J et al (2009) Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma. Am J Surg Pathol 33(7):1037–1041
Alkibay T, Sözen S, Gürocak S et al (2009) Micropapillary pattern in urothelial carcinoma: a clinicopathological analysis. Urol Int 83(3):300–305
Amin MB, Ro JY, el-Sharkawy T et al (1994) Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol 18(12):1224–1232
Johansson SL, Borghede G, Holmäng S (1999) Micropapillary bladder carcinoma: a clinicopathological study of 20 cases. J Urol 161(6):1798–1802
Kamat AM, Gee JR, Dinney CP et al (2006) The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 175(3 Pt 1):881–885 [Erratum in: J Urol 175(5):1967]
Van Oers JM, Wild PJ, Burger M et al (2007) FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumors. Eur Urol 52:760–768
Malats N, Bustos A, Nascimento CM et al (2005) P53 as a prognostic marker for bladder cancer: A metaanalysis and review. Lancet Oncol 6:678–686
Pfister C, Lacombe L, Vezina MC et al (1999) Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors. Hum Pathol 30(11):1350–1355
Kovach JS, Hartmann A, Blaszyk H et al (1996) Mutation detection by highly sensitive methods indicates that p53 mutations in breast cancer may have important prognostic value. Proc Natl Acad Sci USA 93(3):1093–1096
Van Rhijn BW, Vis AN, Kwast TH van der et al (2003) Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 21(10):1912–1921
Van Oers JM, Zwarthoff EC, Rehman I et al (2009) FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol 55:650–657
Shimada K, Nakamura M, De Velasco MA et al (2010) Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma. Cancer Sci 101(1):155–160
Smaratunga H, Khoo K (2004) Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinopathological and immunohistochemical study. Histopathology 45(I):55–64
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Keck, B., Stoehr, R., Wach, S. et al. Das plasmazytoide und mikropapilläre Urothelkarzinom. Urologe 50, 217–220 (2011). https://doi.org/10.1007/s00120-010-2484-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-010-2484-4